TE 8214
Alternative Names: TE-8214Latest Information Update: 11 Sep 2024
Price :
$50 *
At a glance
- Originator Immunwork
- Class Antidiarrhoeals; Antineoplastics; Cyclic peptides; Drug conjugates; Fatty acids; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acromegaly; Neuroendocrine tumours
Most Recent Events
- 05 Sep 2024 Phase-I clinical trials in Acromegaly (SC) (Immunwork pipeline, September 2024)
- 05 Sep 2024 Phase-I clinical trials in Neuroendocrine tumours (SC) (Immunwork pipeline, September 2024)
- 19 Apr 2024 Immunwork plans a phase I trial for Acromegaly (In volunteers)in Australia (SC) in May 2024 (NCT06372652)